1-[4-(Bromomethyl)phenyl]butan-1-one | 864267-47-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-[4-(Bromomethyl)phenyl]butan-1-one
• CAS: 864267-47-0
• 化学式: C₁₁H₁₃BrO
• 分子量: 241.128
• InChiKey: RRDRXBBHYBERBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-[4-(Bromomethyl)phenyl]butan-1-one 在 吡啶 、 溴 、 sodium ethanolate 、 sodium carbonate 、 戴斯-马丁氧化剂 、 溶剂黄146 、 potassium iodide 作用下， 以 乙醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 Diethyl 2-acetamido-2-[[4-(2-oxobutanoyl)phenyl]methyl]propanedioate
  参考文献：
  名称：

  COMPOSITIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACIDS AND POLYPEPTIDES

  摘要：

  公开号：

  EP1828224B1
• 作为产物：
  描述：

  4-甲基苯丁酮 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 苯 为溶剂， 以95%的产率得到1-[4-(Bromomethyl)phenyl]butan-1-one
  参考文献：
  名称：

  WO2008/83346

  摘要：

  公开号：

文献信息

• [EN] THERAPEUTIC INHIBITORY COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS THÉRAPEUTIQUES
  申请人：LIFESCI PHARMACEUTICALS INC

  公开号：WO2015103317A1

  公开（公告）日：2015-07-09

  The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

  该发明提供了Formula I和Formula II的化合物：A-B-C-D-E-F-G-J (I)和C-D-E-F-G-J (II)，其中A、B、C、D、E、F、G和J具有规范中定义的任何值，以及它们的盐。这些化合物对抑制血浆激肽酶和治疗动物中需要抑制血浆激肽酶的疾病或症状是有用的。
• 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：Allen John Gordon

  公开号：US20090099155A1

  公开（公告）日：2009-04-16

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzoazepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is -C≡C-R 10 , -O-R 12 , -S-R 14 , or -NR 24 R 25 ; and other substituents are as defined in the specification.

  本发明提供了式I的6-取代的2,3,4,5-四氢-1H-苯并氮烯作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为-C≡C-R10，-O-R12，-S-R14或-NR24R25；其他取代基如规范中所定义。
• 6 Substituted 2, 3,4,5 Tetrahydro-1H-Benzo[d]Azepines as 5-HT2c Receptor Agonist
  申请人：ALLEN JOHN GORDON

  公开号：US20120028961A1

  公开（公告）日：2012-02-02

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT 2C receptor agonists for the treatment of 5-HT 2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R 6 is —S—R 14 ; and other substituents are as defined in the specification.

  本发明提供了公式I的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环作为选择性5-HT2C受体激动剂，用于治疗5-HT2C相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症：其中：R6为—S—R14；其他取代基如规范中所定义。
• Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
  申请人：Ambrx, Inc.

  公开号：EP2399893A2

  公开（公告）日：2011-12-28

  Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid polypeptides that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such polypeptides. Typically, the modified non-natural amino acid polypeptides include at least one oximine, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid polypeptides and modified non-natural amino acid polypeptides, including therapeutic, diagnostic, and other biotechnology uses.

  本文公开了非天然氨基酸和包括至少一种非天然氨基酸的多肽，以及制造这种非天然氨基酸和多肽的方法。非天然氨基酸本身或作为多肽的一部分，可包括多种可能的官能团，但典型的至少有一个肟基、羰基、二羰基和/或羟胺基。本文还公开了经翻译后进一步修饰的非天然氨基酸多肽、进行此类修饰的方法以及纯化此类多肽的方法。通常，修饰的非天然氨基酸多肽包括至少一个肟基、羰基、二羰基和/或羟胺基团。进一步公开的是使用这种非天然氨基酸多肽和修饰的非天然氨基酸多肽的方法，包括治疗、诊断和其它生物技术用途。
• 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists
  申请人：ELI LILLY AND COMPANY

  公开号：EP2479168A1

  公开（公告）日：2012-07-25

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula I as selective 5-HT2C receptor agonists for the treatment of 5-HT2C associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where: R6 is -S-L-R15 and other substituents are as defined in the specification.

  本发明提供了式 I 的 6-取代 2,3,4,5-四氢-1H-苯并[d]氮杂卓作为选择性 5-HT2C 受体激动剂，用于治疗与 5-HT2C 相关的疾病，包括肥胖症、强迫症、抑郁症和焦虑症： 其中 R6 是-S-L-R15 和其他取代基如说明书中所定义。